Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13834993 | 1.00 | ADRB3 (0.48) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL10009397 | 0.95 | ADRB3 (0.48) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL10009401 | 0.95 | ADRB3 (0.48) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL13835571 | 0.94 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL13835568 | 0.94 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL13976015 | 0.92 | CTSB (0.45) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL13835516 | 0.91 | CYP3A4 (0.45) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL13835515 | 0.91 | CYP3A4 (0.45) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL13975871 | 0.89 | CTSB (0.44) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL13835424 | 0.89 | CTSB (0.44) | ADRB3ADRA2BADRA2CCTSBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951964-B2 | Phenanthridine macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8951964-B2 | Phenanthridine macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20120295842-A1 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295842-A1 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295842-A1 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, HPN, PRSS1 | ADRB3 4212/4885ADRA2B 4747/4885ADRA2C 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.